Is survodutide the same as mazdutide?

No. They are different investigational dual agonists that happen to hit the same two receptors, GLP-1 and glucagon. Survodutide's profile holds a 387-person obesity trial (minus 14.9% versus minus 2.8%) and liver-disease trials in 293 and 216 adults; it is not approved anywhere this site tracks. Mazdutide's profile holds GLORY-1 in 610 adults and a 731-person head to head against dulaglutide, and it is approved in China, not by the FDA. Sharing a receptor pair is not the same molecule, not the same trial, and not the same approval. This site does not rank them. Full records at /compounds/survodutide and /compounds/mazdutide.

Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.

Part of glp-1 and metabolic peptides. Semaglutide, tirzepatide, retatrutide, and the rest of the incretin and glucagon receptor family.